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Abstract 
Background: Human immunodeficiency virus (HIV) and tuberculosis (TB) are the leading independent global causes 
of death among patients with infectious diseases. Additionally, due to the shared immune defense mechanisms, they 
are the leading cause of co-morbidities globally. However, little information was found regarding the proportion of 
TB/HIV co-infection in the study area. Thus, this study determined the proportion and associated factors of TB/HIV 
co-infection.
Methods: All TB patients treated from January/2011 to December/2014 were included in this study. Data were col-
lected from three health centers namely; Kobo, Robit and Gobiye. Data were entered, cleared, and analyzed using 
SPSS version 20. Frequency, percentage, median and range were used to present the data. To assess the associated 
factors, logistic regression was employed.
Results: Of the total 990 TB patients enrolled in the study, 98.2 % were screened for HIV; of these, 24.3 % were co-
infected with TB and HIV. The odds of having TB/HIV co-infection were 3.4 times higher among in the age group of 
25–45 years compared to older (≥45 years) age TB patients (OR = 3.4; 95 % CI 2–5). Moreover, the odds of having TB/
HIV co-infection were 2.8 and 1.7 times higher among smear positive and smear negative patients with pulmonary TB 
respectively than patients with extra pulmonary TB. Of 236 co-infected patients, 71.2 % took co-trimoxazole preven-
tive therapy and 76.3 % took antiretroviral treatment.
Conclusion: TB/HIV co-infection is one of the serious public health problems in the study area. Thus, Collaborative 
TB/HIV activities that reduce the co-morbidities and mortalities should be addressed.
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Background
Human immunodeficiency virus (HIV) and tuberculosis 
(TB) are the first and second leading causes, respectively 
of death globally due to a single infectious agent [1]. Due 
to the shared immune defense mechanisms between the 
two diseases, TB is a leading preventable cause of death 
among people living with HIV and vice versa [2–4]. Most 
of these deaths occur in resource-limited settings [5] like 
Ethiopia.
According to 2011 Ethiopian demographic health sur-
vey, the prevalence of HIV was 1.5  % [6]. Similarly, in 
urban and rural Amhara region where this study was 
conducted, the prevalence of HIV was 10.7 and 1.5  %, 
respectively [7].
The prevalence of TB in Ethiopia was 211/100,000 [8]. 
Tuberculosis threatens the poorest and most marginalized 
populations [9, 10]. The resurgence of TB has been fueled 
by multi factors like HIV and drug resistant TB. And also, 
the current increasing HIV associated tuberculosis shifted 
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the clinical pattern TB towards smears negative pulmo-
nary (PTB−) and extra pulmonary TB (EPTB) [11, 12].
The prevalence of TB among HIV positive clients 
in Ethiopia was 7.8  % and in Amhara region, it it was 
4.9  % [13]. Conversely, the prevalence of HIV among 
TB patients in Ethiopia and Amhara region was 20 and 
26.5 %, respectively [13].
Information is limited on the proportion of TB, HIV 
and TB/HIV co-infection in the study area. Also, stud-
ies done nationally and in Amhara region could not 
reflect the real TB/HIV situation in the study area due 
to methodological variation [13–15]. Unlike others, this 
study used all TB registers data across 2011–2014 among 
TB clinics who were treating TB patients from urban 
and rural area of Kobo and Raya kobo woredas, East of 
Amhara and/or north eastern Ethiopia to assess the pro-
portion of TB/HIV co-infection and associated factors.
Methods
Study setting and period
All patients diagnosed and treated from January/2011 to 
December/2014 were included in this study. Health cent-
ers in Ethiopia in general are a primary health care unit 
that serves a population of 15,000–25,000 and is com-
prised of clinics like TB, antiretroviral treatment (ART), 
maternal and child health, and outpatient. Public health 
officers and clinical nurses with BSc degree work as prac-
titioner.  Moreover, most of laboratory and pharmacy 
professionals were diploma holder.
Diagnoses of pulmonary TB in the health centers were 
done using clinical and Ziehl-Neelsen (ZN) microscopy 
information. Clinical specimen for diagnosis of pulmo-
nary TB was collected using spot-morning-spot sam-
ple collection strategy. EPTB cases were diagnosed and 
referred from nearby Kobo, Woldiya, Dessie, Alamata 
hospitals and privates clinics. Diagnosis of EPTB was 
mainly using clinical history with X-ray, ultrasound and/
or pathologic techniques. For those diagnosed with active 
TB, the standard TB treatment regimen, 2(RHZE)/4 (RH) 
and 2S (HRZE)/1(HRZE)/5(HR)E was started for new 
and previously treated TB patients, respectively [16]. 
For HIV screening, nationally approved rapid serologi-
cal testing algorisms (KHB → StatPak → Uni-gold) were 
used. As soon as HIV is identified in a TB patient, the 
patient is enrolled to HIV chronic care and co-trimoxa-
zole preventive therapy (CPT) started [17].
Operational definitions
Cured
A patient with bacteriologically confirmed pulmonary TB 
at the beginning of treatment who was smear or culture-
negative in the last month of treatment.
Treatment completed
A patient with TB who completed treatment without evi-
dence of failure, but with no record of sputum smear or 
culture results, in the last month of treatment.
Treatment success (good treatment outcome)
The sum of cured and treatment completed.
Died
A TB patient who died from any cause during treatment.
Failed
A TB patient whose sputum smear or culture is positive 
at month 5 or later during treatment.
Lost to follow‑up
A TB patient who did not start treatment or whose treat-
ment was interrupted for two consecutive months or 
more.
Poor treatment outcome
The sum of treatment failed, died and loss to follow up.
Inclusion and exclusion criteria
Patients with TB whose record data were missing age, sex 
and type of TB were excluded from the study. Patients 
with complete demographic and clinical data (regardless 
of age groups and sex, type of TB and HIV status) were 
included in the study.
Sample size
A total of 990 patients with TB were treated between Jan-
uary/2011 and December/2014. All these patients were 
included in the study.
Data collection and tools
Data were collected from three health centers namely 
Kobo, Robit and Gobiye. Demographic and clinical data 
such as age, sex, type of TB, HIV, CPT and ART status 
were retrieved from TB registry.
Data analysis
All data were entered, cleared, and analyzed using SPSS 
statistical software package (IBM Corp. Released 2011. 
IBM SPSS Statistics for Windows, Version 20.0. Armonk, 
NY: IBM Corp.). Frequency, percentage, median and 
range were used to present the data. To assess the asso-
ciation between dependent and independent variables, 
logistic regression was used. Associations between vari-
ables were determined using odds ratio and 95 % confi-
dence interval (CI). P value of <0.05 was considered as 
statistical significance.
Page 3 of 6Mekonnen et al. BMC Res Notes  (2015) 8:666 
Ethical considerations
Ethical clearance was obtained from Amhara Regional 
Ethical Review Committee (RERC) with reference num-
ber of HRTT/11/71/2014. In addition, a support letter 
was written to Zonal Health Department and Kobo and 
Raya Kobo Woreda Health Offices. Data did not include 
the patient’s name and kept confidential. The data were 
used for the purpose of the study only.
Results
Of the total 990  TB patients enrolled to this study, 551 
(55.7  %) were males. The median age of participants 
were 29 years (range 1–84). The majority of TB patients 
were in the age groups of 25–45 years. The proportion of 
EPTB, PTB− and PTB+ were 462 (46.7 %), 332 (33.5 %) 
and 196 (19.8 %), respectively (Table 1).
Among the total TB patients, 972 (98.2  %) were 
screened for HIV. The remaining 18 (1.8  %) patients 
had no HIV status data. Of the total HIV screened TB 
patients, the proportion of TB/HIV co-infection was 236 
(24.3 %). The odds of having TB/HIV co-infection was 3.4 
times higher in the age group of 25–45 year old as com-
pared to patients with ≥46 years of age (AOR = 3.4; 95 % 
CI 2–5; P = 0.00). Moreover, the odds of having TB/HIV 
co-infection were 2.8 and 1.7 times higher among PTB+ 
and PTB− patients than EPTB, respectively (Table 2). Of 
that TB/HIV co-infected 71.2 and 76.3 % took CPT and 
ART, respectively. The proportion of treatment success 
was 86.2 % (Table 1).
Discussion
In the present study, 98.1 % of TB patients were screened 
for HIV which was higher than the latest national data, 
71 % [10, 18]. In 2013, 48 % of TB patients globally had 
a documented HIV test result. In the African Region, 
76  % of TB patients knew their HIV status [8]. Among 
Ethiopian regional states, the highest proportion of peo-
ple living with HIV/AIDS (PLHIV) was seen in Amhara 
[7]. This showed that HIV screening practice is better 
in Amhara region and in the study area in particular. 
Moreover, it seems that there was  better commitment 
from health professionals and local administrative bod-
ies in terms of screening, communication and social 
mobilization.
Among those HIV screened TB patients; the pro-
portion of TB/HIV co-infection was 24.3  % which was 
much higher than reports from Ethiopia, 6.3–20  % [10, 
13, 16, 17, 19]. It was also higher when compared to a 
similar study in Nigeria, 20.5  % [20]. Overlapping co-
morbid diseases are growing in resource-limited coun-
tries like Ethiopia [11]. This might be due multi-TB and 
HIV related risk factors. First, it is well known that, peo-
ple in this area have the practice of dating sisters-in-law 
or brothers-in-law  [observation]. This practice would 
have a significant impact on HIV transmission. Second, 
the community especially farmers in the study area are 
well known drinkers of local beer (Teji in local Amharic 
Language), this action might push people to have unpro-
tected sexual practice. Third, the area is one of draughts 
prone and food unsecured area [21]. Thus, there are 
many migrants to Middle East for home maid and daily 
labor after having divorced. Moreover, so many beautiful 
ladies enforced to sex work due to financial constraints. 
Furthermore,  the associations between poverty and TB 
have been known [9, 10, 22–24]. This might increase TB/
HIV co-infection cases in the area. Fourth, the presence 
of many illegal private TB drug sellers in the area might 
contributed for high TB and drug resistant TB. Lastly, 
high number of HIV means, there would be many HIV 
Table 1 Demographic and  tuberculosis profile of  TB 
patients, Northeastern Amhara, Ethiopia, 2015
ART antiretroviral therapy, CPT co-trimoxazole preventive therapy, EPTB extra 
pulmonary TB, HIV human immunodeficiency virus, PTB− smears negative 
pulmonary TB, PTB+ smear-positive pulmonary TB, TB tuberculosis
Variables Frequency (N) Percentage (%)
Sex
 Male 551 55.7
 Female 439 44.3
Age (years)
 ≤24 326 32.9
 25–45 458 46.3
 ≥46 206 20.8
Types of TB
 PTB+ 196 19.8
 PTB− 332 33.5
 EPTB 462 46.7
Treatment outcome
 Poor 96 9.7
 Success 853 86.2
 Transfer out 30 3
 Unknown 11 1.1
HIV status
 HIV positive 236 24.3
 HIV negative 736 74.3
 Unknown 18 1.8
 Total 990 100
Variables Frequency (N = 236) Percentage (%)
CPT prophylaxis
 Yes 168 71.2
 No 68 28.8
ART status
 On ART 180 76.3
 Pre-ART 56 23.6
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associated tuberculosis. All  these factors might have 
direct or indirect contribution to the high TB/HIV co-
infection rate. To identify which factors are more impor-
tant than other, population based study must be done.
In contrast, our TB/HIV proportion data  was lower 
than studies done in Debre markos 44  % [14], Dabat-
Gondar 34 % [15] and Kenya 41.8 % [25]. This might be 
due to differences in the study site. These studies were 
conducted at referral and teaching hospitals where 
many chronic, end stage diseases and referral cases 
were seen. Our study was conducted in health centers. 
Globally, 13–14.8  % of people who developed TB are 
HIV positive [7, 9, 26, 27]. Prevalence of TB/HIV co-
infection was 31.25  % in African countries [7, 28]. In 
2012, the prevalence of TB/HIV co-infection was 43 % 
in Africa [9] and as high as 50–80  % in parts of sub-
Saharan Africa [27].
The ART coverage in the present study was 
higher, 76.3 %, as compared to a WHO report from Ethi-
opia, 68 %, but lowers than WHO target of 100 % [10, 18]. 
Other reports showed that ART coverage was 50.5 and 
40.2 % in Ethiopia and Amhara region [13], respectively. 
This might be due to proximity of health centers to the 
community. Moreover, communication and social mobi-
lization might be done by local stake holders to diagnose 
and linked more patients to ART. Furthermore, according 
to unpublished reports from the community, the practice 
of safe sex and use of condoms is low but people’s aware-
ness of the value of ART is high.
The proportion of TB/HIV co-infection among women 
was relatively higher in the present study (Table 2). This 
corroborates WHO reports. More young women noti-
fied with TB/HIV than young men in Africa [29–31]. Out 
of the 346 TB cases in Kenya, 41.8 % of were co-infected 
and female to male TB/HIV co-infection prevalence 
ratio was 1.35:1 [25]. The possible reason might be due 
to socio economic factors and health seeking behavior of 
women. As compared to men, women have no control of 
financial resources at household levels.  Moreover, there 
is higher rate of transient and permanent immune sup-
pression with pregnancy, lactation and HIV in women 
than men [29].
In the present study, TB/HIV co-infection was sig-
nificantly associated with age group of 25–45 years and 
PTB+, P < 0.05 (Table 2). It was well known that TB and 
HIV affect reproductive age groups of the population [8]. 
In contrast to the literature evidence, PTB+ was signifi-
cantly associated with HIV than PTB− and EPTB in the 
present study. This might be due to multi factors. First, 
the relatively higher ART and CPT coverage was found in 
the study area. If PTB+/HIV co-infected people adhered 
well on ART and CPT, they would have high level of 
innate and cell mediated immunity. Thus, these people 
would have high probability for being smear positive. 
Second, it is known that EPTB and PTB− are HIV asso-
ciated than PTB+ [12]. However, this study could not dif-
ferentiated HIV associated TB from non HIV associated 
TB. Thus, if TB infection and diagnosis occurred before 
Table 2 Regression analysis showing associated factors for TB/HIV co-infection, Northeastern Amhara, Ethiopia, 2015
AOR adjusted odds ratio, ART antiretroviral therapy, COR crude odds ratio, CPT co-trimoxazole preventive therapy, EPTB extra pulmonary TB, HIV human 
immunodeficiency virus, PTB− smears negative pulmonary TB, PTB+ smear-positive pulmonary TB, TB tuberculosis
Predictor variables TB–HIV confection COR (95 % CI), P value AOR (95 % CI), P value
Yes N (%) No N (%) Total N
Sex
 Female 113 (25.7) 326 (74.3) 439 1.2 (0.9–1.6), 0.2 1.2 (0.9–1.6), 0.17
 Male 123 (22.3) 428 (77.7) 551 1
Age
 ≤24 44 (13.5) 282 (86.5) 326 0.9 (0.57–1.6), 0.85 0.9 (0.57–1.6), 0.85
 25–45 163 (29.4) 295 (70.6) 418 3.4 (2–5), 0.00 3.4 (2–5), 0.00
 ≥46 29 (14.1) 177 (85.9) 206 1 1
Types of TB
 PTB+ 71 (36.2) 125 (63.8) 196 2.8 (1.9–4), 0.00 2.2 (1.4–3.3), 0.00
 PTB− 87 (26.2) 245 (73.8) 332 1.7 (1.2–2.5), 0.002 1.9 (1.3–2.8), 001
 EPTB 78 (16.9) 384 (83.1) 462 1 1
TB treatment outcome
 Unknown 4 (36.4) 7 (63.6) 11 2 (0.58–6.98), 0.26 2 (0.56–7.3), 0.23
 Transfer out 5 (16.7) 25 (83.3) 30 0.7 (0.26–1.8), 0.48 0.64 (0.23–1.75), 0.38
 Poor 39 (40.6) 57 (59.4) 96 2.4 (1.56–3.75), 0.00 2 (1.2–3.1), 0.003
Success 188 (22) 665 (78) 853 1 1
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HIV infection, the proportion of PTB+/HIV would be 
higher than EPTB/HIV and PTB−/HIV co-infection. The 
third, possible reason might be due to, over-diagnosis of 
EPTB and PTB− cases. Because, higher proportion of 
EPTB and PTB− cases were diagnosed and transferred 
in from private clinics which did not have any imaging 
and pathologic techniques. This justification was sup-
ported by, health professionals in the study area (expert 
opinion). Additionally, Ehlers et  al. reported that only 2 
of the 76 PTB− patients had been diagnosed correctly 
[32]. Moreover, a study by Iwnetu et al. concluding that 
up to 15 % of all EPTB cases could be wrongly diagnosed 
[33]. The last possible reason might be due to zoonotic 
transmission of TB and genetic features of the pathogen 
and/or the host population. This was in line with the lat-
est report by Berg et al. According to this report, having 
regular and direct contact with live animals, was a signifi-
cant risk factor for lymph node (TBLN) when compared 
to pulmonary TB. In addition, no association was found 
with HIV infection [34]. The study area is known with 
large live stock populations, sharing of shelter between 
human and livestock, use of raw meat and milk.
TB/HIV co-infection was significantly associated with 
poor TB treatment outcome in the present study (AOR: 
2; 95  % CI 1.2–3.1; P =  0.003) (Table  2). This might be 
due to the presence of TB and HIV drug interaction that 
make low adherence to anti-TB drugs. Tuberculosis case-
fatality rates in Africa were 16–35  % among HIV posi-
tives and 4–9  % in HIV-negative patients [35, 36]. This 
indicates that full DOTS implementation alone is insuffi-
cient to control TB. Thus, collaborative TB/HIV activities 
aimed to reduce the burden of diseases are very impor-
tant [37].
Conclusion and recommendations
The proportion of TB/HIV co-infections were higher in 
the study area which indicates that people’s awareness 
on transmission and control mechanism of TB and HIV 
is low. On the other hand, 98.1  % of TB patients were 
screened for HIV but ART coverage was 76.3  % which 
was lower than WHO target of 100 %. Moreover, propor-
tion of TB/HIV co-infection was associated with women, 
age group of 25–45 years, PTB+ and poor TB treatment 
outcome. Hence, sex and age targeted interventions like 
awareness creation training should be given to female 
and sexually active age (25–45 years) groups of the popu-
lation. Moreover, communication and social mobilization 
must further strengthen to achieve 100  % ART cover-
age. TB/HIV co-infected people were found to be more 
infectious. Thus, the laboratory professionals’ capac-
ity must be strengthen to detect those infectious cases. 
Additionally, diagnostic quality of EPTB and PTB− 
must strengthen by implementing rapid and sensitive 
diagnostic technologies like, Fluorescent Microscopy, 
Xpert MTB/Rif. Furthermore, to have good TB treatment 
outcome, prompt and community involved DOTS based 
anti-TB treatment should be in place.
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